Namodenoson Treatment of Advanced Pancreatic Cancer
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Pancreatic Adenocarcinoma|Pancreatic Cancer
DRUG: Namodenoson 25mg
Adverse Events, Assessments of adverse events (AEs) will include characterization of type, incidence, severity (graded by CTCAE v5.0), seriousness, and relationship to treatment., Every 2 weeks, assessed up to 1 year|Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), which is a scale of functioning, from 0 (normal activity) to 5 (death), Every 2 weeks, assessed up to 1 year
Objective response rate, clinical activity measure of objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), measured by computed tomography (CT) scan, positron emission tomography (PET) CT, and/or magnetic resonance imaging (MRI), Every 8 weeks, assessed up to 1 year|Progression free survival, clinical activity measure of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), measured by computed tomography (CT) scan, positron emission tomography (PET) CT, and/or magnetic resonance imaging (MRI), Every 8 weeks, assessed up to 1 year|Disease control rate, clinical activity measure of disease control rate (DCR), Every 8 weeks, assessed up to 1 year|Duration of response, clinical activity measure of duration of response (DoR), defined as the time from first response to disease progression or death from any cause, whichever occurs first, Every 8 weeks, assessed up to 1 year|Overall survival, clinical activity measure of overall survival (OS), including death from any cause, Every 8 weeks, assessed up to 1 year
Quality of Life evaluation with EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30), in which summary scores range from 0 to 100, with higher scores indicating better health-related quality of life, Every 4 weeks, assessed up to 1 year|Quality of Life evaluation with EORTC QLQ-PAN26, European Organization for Research and Treatment of Cancer Quality of Life pancreatic adenocarcinoma-specific module, the EORTC QLQ-PAN26, in which summary scores range from 0 to 100, with higher scores indicating better health-related quality of life, Every 4 weeks, assessed up to 1 year|Pharmacokinetics of namodenoson: Cmax, Maximum plasma concentration of namodenoson, Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1|Pharmacokinetics of namodenoson: Cmin, Minimum plasma concentration of namodenoson, Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1|Pharmacokinetics of namodenoson: AUC(0-12), Area under the curve of namodenoson plasma exposure from 0-12 hours post-dose, Cycle 1, day 1 (each cycle is 28 days); Cycle 1, day 15, and Cycle 2, day 1|Cancer antigen 19-9 (CA 19-9), Change from baseline in Cancer antigen 19-9 (CA 19-9) biomarker during treatment, Every 4 weeks, assessed up to 1 year|Carcinoembryonic Antigen (CEA), Change from baseline in Carcinoembryonic Antigen (CEA) biomarker during treatment, Every 4 weeks, assessed up to 1 year
All patients will receive the study drug twice daily. The study drug is given as a capsule, orally (by mouth). Patients will be monitored regularly for safety. Tumor imaging will be performed approximately every two months. Patients can decide to stop the treatment with study drug at any time.